2'- hydroxy- 2,4,4',5,6'- pentamethylchalcone

01/01/2017 - "In summary, our results showed how rubone acts as an efficient small-molecule modulator of miR-34a to reverse chemoresistance and further enhance the therapeutic efficacy of paclitaxel in paclitaxel-resistant prostate cancer. "
01/01/2017 - "Micellar Delivery of miR-34a Modulator Rubone and Paclitaxel in Resistant Prostate Cancer."
01/01/2017 - "In this study, we demonstrate that codelivery of paclitaxel and 2'-hydroxy-2,4,4',5,6'-pentamethoxychalcone (termed rubone) drives upregulation of miR-34a and chemosensitizes paclitaxel-resistant prostate cancer cells, killing both cancer stem-like cells (CSC) and bulk tumor cells. "
01/01/2019 - "Herein, we demonstrated the fabrication of a pH and glutathione (GSH) sensitive nanocarrier for co-delivery of docetaxel (DTX) and rubone (RUB), a miR-34 activator for targeting CSCs, for the treatment of taxane resistant (TXR) prostate cancer. "

07/13/2016 - "However, the extremely low aqueous solubility of Rubone hampers its use in cancer treatment. "
01/01/2015 - "Restoration of miR-34a by Rubone represents a promising therapeutic approach against cancer. "
01/01/2015 - "In a recent issue of Cancer Research, we describe a small molecule, Rubone, with strong anticancer activity. "
11/01/2014 - "Taken together, our results offer a preclinical proof of concept for Rubone as a lead candidate for further investigation as a new class of HCC therapeutic based on restoration of miR34a tumor-suppressor function."
07/13/2016 - "In vivo experiments showed that Rubone can be preferentially delivered into tumor tissues by CMD-stabilized PEI-PCL nanoparticles after intravenous administration and significantly inhibited tumor growth. "

01/01/2015 - "Rubone selectively restored miR-34a expression in hepatocellular carcinoma cells in which miR-34a was silenced. "